The associations of S100 gene expression with our ex vivo drug sensitivity data revealed S100A8, S100A9, and S100A12 expression inversely correlated with bortezomib, carfilzomib and panobinostat sensitivity, all of which have been approved for the treatment of MM. Here, S100A1 is linked to Miyoshi myopathy.